High rate of adenovirus detection in gastrointestinal biopsies of symptomatic stem cell transplant recipients

• DOI: 10.1111/ctr.15098
• Publication Date: 2023-08-11T03:11:04Z
• Authors: Hagar Z. Pikkel‐Geva; Sigal Grisariu; Mila Rivkin; Polina Stepensky; Jacob Strahilevitz; Dina Averbuch; Caplan Orit; Ehud Even‐Or; Irina Zaidman; Eran Zimran; Dana G. Wolf; Batia Avni
• Keywords: Adult; Adenovirus Infections, Human; Adenoviridae Infections; Adenoviruses, Human; Biopsy; Hematopoietic Stem Cell Transplantation; Humans; Prospective Studies; Child; 3. Good health; Adenoviridae; Retrospective Studies

AbstractObjectivesThe gastrointestinal (GI) tract is a major human adenovirus (HAdV) replication site in patients undergoing hematopoietic stem cell transplantation (HSCT), yet the prevalence and correlates of HAdV GI infection in this setting have remained poorly recognized, especially among adult HSCT recipients.Design or methodsWe retrospectively studied the prevalence and risk factors of HAdV GI‐tissue infection in HSCT recipients (73 adults and 15 children) with GI symptoms who underwent GI‐tissue biopsy between January‐2012 and December‐2017. The presence of HAdV in the GI tissues was determined by real‐time PCR.ResultsHAdV GI‐tissue infection was detected in 21 (23.9%) patients, with similar infection rates identified in adults and children. GI‐tissue detection was more common at late (>100 days) compared to early times post‐transplantation (50% vs. 12.9%, p < .001). The presence of bloody diarrhea, Arab ethnicity (p = .014) and concurrent cytomegalovirus GI‐tissue detection (p = .025) were significantly correlated with HAdV GI‐tissue infection, while chronic graft versus host disease was of borderline association (p = .055).ConclusionsOur findings reveal a high rate and new clinical‐demographic correlates of HAdV GI‐tissue infection in adult and pediatric HSCT recipients with GI symptoms. The findings highlight the need for future prospective studies to assess the relatedness of HAdV infection to the GI symptoms, and the prevalence, impact, and treatment of HAdV GI infection in HSCT recipients.